Skip to main content
OK BIOTECH logo

OK BIOTECH — Investor Relations & Filings

Ticker · 4155 ISIN · TW0004155007 TW Manufacturing
Open in API
Filings indexed 1,729 across all filing types
Latest filing 2026-05-27 Share Issue/Capital Cha…
Country TW Taiwan
Listing TW 4155

About OK BIOTECH

http://www.okbiotech.com

OK Biotech Co., Ltd. is a medical device company specializing in the research, development, manufacturing, and global distribution of diagnostic and home healthcare solutions. Established in 2004, the company focuses on blood glucose monitoring systems, including high-precision meters and test strips, alongside over-the-counter (OTC) hearing aids and multiple frequency therapy devices. OK Biotech provides comprehensive services ranging from product design to complete factory setup solutions, supporting partners from initial planning through to mass production. By leveraging advanced R&D and production technologies, the company delivers reliable OEM and ODM solutions designed for both personal wellness and professional clinical applications. Its commitment to technical innovation ensures the delivery of high-quality medical instruments and tailored healthcare support to a global market.

Recent filings

Filing Released Lang Actions
115年5月變更登記
Share Issue/Capital Change Classification · 89% confidence The document is a corporate announcement from the public information observation station detailing the company's share capital structure: authorized vs issued shares, face value, and history of capital increases, decreases, and share cancellations. This matches the definition of a Share Issue/Capital Change (SHA) filing.
2026-05-27 Chinese
公司基本資料
Regulatory Filings Classification · 85% confidence The document is a static corporate profile disclosure from the Taiwanese public information observatory (“公開資訊觀測站”) listing basic company data (stock code, address, chairperson, auditor, shares, etc.). It does not present financial statements, meeting materials, report publication notices, or any specific transaction or event. It falls under the fallback category for general regulatory disclosures. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-05-27 Chinese
本公司收回已發行之限制員工權利新股辦理註銷減資 變更登記完成
Share Issue/Capital Change Classification · 85% confidence The document is an announcement by the issuer that it has retrieved and cancelled previously issued restricted employee shares, resulting in a capital reduction and registration of the change in paid‐in capital and number of shares outstanding. It provides details on the regulatory approval date, registered reduction, effect on capital and book value per share. This is an announcement of a corporate capital change (share cancellation), matching the Share Issue/Capital Change category (SHA).
2026-05-27 Chinese
115年第1季海外子公司投資
Interim / Quarterly Report Classification · 86% confidence The document is a substantive table of financial data for the first quarter (115年1季) showing equity-method investments, ending balances, and recognized gains or losses. It is part of a quarterly report with actual financial statements content, not merely a notice or announcement. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-14 Chinese
115年第1季財務報告書 — 202601_4155_AI1.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a consolidated financial report and accountant’s review (PwC review report) covering the first quarter (Q1) of fiscal years 115 and 114, including balance sheets, income statements, cash flows, and notes prepared under IFRS 34 (interim reporting). It contains substantive financial statements for a shorter period than a full year. Therefore, it matches the definition of an Interim / Quarterly Report. Q1 2026
2026-05-14 Chinese
115年第1季權益變動表
Interim / Quarterly Report Classification · 93% confidence The document is a consolidated statement of changes in equity for the first quarter (民國115年第1季) presenting detailed financial line items (opening balance, dividends, net income, other comprehensive income, stock-based payments, ending balance) and a comparative prior period. This is substantive financial data for a quarterly period, indicating it is part of an Interim/Quarterly Report rather than an announcement or summary. Thus, it should be classified as IR. Q1 2026
2026-05-14 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.